Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7.

OBJECTIVE Intracarotid infusion of the bradykinin analog, RMP-7, can increase permeability in brain tumor capillaries. This study sought to determine the following: 1) the unidirectional transport, Ki, of radiolabeled [14C]carboplatin into brain tumors with either intravenous or intracarotid RMP-7 infusions; 2) the duration and extent of increased permeability in tumor capillaries during continuous RMP-7 infusions; and 3) the effect on survival of carboplatin combined with RMP-7 treatment in rats with gliomas. METHODS Wistar rats with RG2 gliomas were used, and a unidirectional transfer constant, Ki, was determined using quantitative autoradiography. In the survival study, the rats were treated with intra-arterial carboplatin and RMP-7 at Days 5 and 7 after tumor implantation. RESULTS Intracarotid infusion of RMP-7 for 15 minutes increased the transport of [14C]carboplatin to tumors by 2.7-fold, as compared with saline infusion alone (P < 0.001). The transports of [14C]dextran and [14C]carboplatin into tumors were significantly higher with 15 minutes of intracarotid infusion of RMP-7 (0.1 microgram/kg/min), compared to those with 10-, 30-, or 60-minute infusions (P < 0.01). Rats treated at Days 5 and 7 after tumor implantation with carboplatin alone (10 mg/kg) exhibited a modest increase in survival at 31 days (37%, compared to < 10% of controls), while those given the combination of carboplatin with RMP-7 exhibited a significantly higher survival rate (74%). CONCLUSION Intracarotid infusion of RMP-7 can selectively increase transport of carboplatin into brain tumors and results in higher survival in rats with gliomas. These findings support the use of intracarotid infusion of RMP-7 to enhance the delivery of carboplatin to patients with malignant brain tumors.

[1]  K. Black,et al.  Intracarotid infusion of bradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors , 1994, Brain Research.

[2]  K D Pettigrew,et al.  Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. , 1978, The American journal of physiology.

[3]  K. Black,et al.  Increased opening of blood-tumour barrier by leukotriene C4 is dependent on size of molecules. , 1992, Neurological research.

[4]  D. Robertson,et al.  Pharmacological Modification of Bradykinin Induced Breakdown of the Blood-brain Barrier , 1986, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[5]  E P Frenkel,et al.  Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[6]  S. Rapoport,et al.  Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors. , 1984, Federation proceedings.

[7]  J. Wells,et al.  Stimulation of Na+/H+ antiport is an early event in hypertrophy of renal proximal tubular cells. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[8]  D. Groothuis,et al.  The effect of hyperosmotic blood—brain barrier disruption on blood‐to‐tissue transport in ENU‐induced gliomas , 1987, Annals of neurology.

[9]  G. Lapin,et al.  Effect of hyperosmotic blood-brain barrier disruption on transcapillary transport in canine brain tumors. , 1990, Journal of neurosurgery.

[10]  K. Black,et al.  Enzymatic barrier protects brain capillaries from leukotriene C4. , 1994, Journal of neurosurgery.

[11]  R. Heller-Harrison,et al.  The bradykinin analog RMP-7 increases intracellular free calcium levels in rat brain microvascular endothelial cells. , 1994, The Journal of pharmacology and experimental therapeutics.

[12]  D. Stewart,et al.  Phase I study of intracarotid administration of carboplatin. , 1992 .

[13]  K. Black,et al.  Selective blood-tumor barrier disruption by leukotrienes. , 1992, Journal of neurosurgery.

[14]  W. Pardridge,et al.  Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier. , 1987, Biochemical and biophysical research communications.

[15]  M. Fukui,et al.  Intracarotid histamine infusion increases blood tumour permeability in RG2 glioma. , 1994, Neurological research.

[16]  M. Moskowitz,et al.  Synthesis of compounds with properties of leukotrienes C4 and D4 in gerbil brains after ischemia and reperfusion. , 1984, Science.

[17]  K. Black,et al.  Increased leukotriene C4 and vasogenic edema surrounding brain tumors in humans , 1986, Annals of neurology.

[18]  E P Frenkel,et al.  Osmotic blood-brain barrier modification and combination chemotherapy: concurrent tumor regression in areas of barrier opening and progression in brain regions distant to barrier opening. , 1984, Neurosurgery.

[19]  C. Pirola,et al.  Central bradykininergic system in normotensive and hypertensive rats. , 1992, Clinical science.

[20]  K. Black,et al.  Intracarotid Infusion of Leukotriene C4 Selectively Increases Blood-Brain Barrier Permeability after Focal Ischemia in Rats , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[21]  S. Carter,et al.  Carboplatin: the clinical spectrum to date. , 1985, Cancer treatment reviews.

[22]  W. T. Shults,et al.  Maculopathy associated with combination chemotherapy and osmotic opening of the blood-brain barrier. , 1986, American journal of ophthalmology.

[23]  S. Nishio,et al.  Hyperosmotic blood-brain barrier disruption in brains of rats with an intracerebrally transplanted RG-C6 tumor. , 1987, Journal of neurosurgery.

[24]  F. Hazama,et al.  NEUROTOXICITY OF VINCRISTINE AFTER THE OSMOTIC OPENING OF THE BLOOD‐BRAIN BARRIER , 1983, Neuropathology and applied neurobiology.

[25]  B. Jeremic,et al.  Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Fishman,et al.  Induction of brain edema following intracerebral injection of arachidonic acid , 1983, Annals of neurology.

[27]  W. Pardridge,et al.  Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport. , 1987, The Journal of biological chemistry.

[28]  W. Yung,et al.  Intravenous carboplatin for recurrent malignant glioma: a phase II study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Prados,et al.  Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Minna,et al.  Osmotic blood-brain barrier modification: monoclonal antibody, albumin, and methotrexate delivery to cerebrospinal fluid and brain. , 1985, Neurosurgery.

[31]  N. Hooper,et al.  Characterization of Neuronal and Endothelial Forms of Angiotensin Converting Enzyme in Pig Brain , 1991, Journal of neurochemistry.

[32]  Y. Z. Ziylan,et al.  Effect of Dexamethasone on Transport of α‐Aminoisobutyric Acid and Sucrose Across the Blood‐Brain Barrier , 1988, Journal of neurochemistry.

[33]  K. Black,et al.  Leukotrienes increase blood‐brain barrier permeability following intraparenchymal injections in rats , 1985, Annals of neurology.

[34]  J. Vane,et al.  Conversion of Angiotensin I to Angiotensin II , 1967, Nature.

[35]  N. Tamaki,et al.  The effect of leukotriene C4 on the permeability of brain capillary endothelial cell monolayer. , 1994, Acta neurochirurgica. Supplementum.

[36]  K. Black,et al.  Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors. , 1994, Journal of neurosurgery.

[37]  K. Black,et al.  Selective opening of the blood-tumor barrier by intracarotid infusion of leukotriene C4. , 1990, Journal of neurosurgery.

[38]  S. Rennard,et al.  Role of peptidases in bradykinin-induced increase in vascular permeability in vivo. , 1992, Circulation research.

[39]  K. Black,et al.  Bradykinin Selectively Opens Blood-Tumor Barrier in Experimental Brain Tumors , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[40]  W. J. Oakes,et al.  Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  M. Tableman,et al.  Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. , 1995, Neurosurgery.

[42]  D. Bigner,et al.  Permeability of Different Experimental Brain Tumor Models to Horseradish Peroxidase , 1982, Journal of neuropathology and experimental neurology.